• About
  • Meet The Team
  • Privacy Policy
Saturday, January 23, 2021

Stocks Telegraph
  • Login
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers
No Result
View All Result
Stocks Telegraph
No Result
View All Result

Is Pfizer Inc. (NYSE: PFE) A Good Investment?

by Hasnain R
September 15, 2020
in Featured, Investing
Share on FacebookShare on Twitter

Shares of Pfizer Inc. (NYSE: PFE) traded up 2.61% after gaining +0.94 on Monday as it may be the first to disclose the late-stage study result from its trials with partner BioNTech SE. Pfizer Inc. is currently conducting one of the most advanced trials of a vaccine for novel coronavirus.

It has commenced the Phase 2/3 study of BNT162b2, a most advanced coronavirus vaccine candidate in July. Almost 30,000 participants were enrolled in the trial who received two doses of the vaccine candidate.

Pfizer CEO Albert Bourla revealed that the FDA committee will gather to discuss vaccines on Oct 22. CEO said that the company has a deep understanding of this matter and it will be able to present the efficacy data of Phase 3 before the end of October.

He said that the company is not bound to any deadline. Albert Bourla said that FDA is searching for companies to review their vaccines that are at least 50% effective. Pfizer is hoping for a better result as its Phase 3 trial with 30,000 people is almost completed.

Goldman Sachs labeled this a vaccine trade as the investors were attracting towards stocks that were developing a vaccine or any treatment of diseases and they dumped the stock soon after hearing the good news. The same thing happened with Gilead Sciences as its shares tumbled down after it has got the regulatory approval for its antiviral medicine of COVID-19.

Pfizer Inc. (NYSE: PFE) share price went from a low point around $27.88 to briefly over $40.97 in the past 52 weeks, though shares have since pulled back to $37.01. Pfizer Inc. has moved up 32.75% from its 52-weeks low and moved down -9.67% from its 52-weeks high. Pfizer Inc.’s market cap has remained high, hitting $203.27 billion at the time of writing. If we look at its liquidity, it has a current ratio of 1.40.

Pfizer Inc and BioNTech SE have recently disclosed that they striving to secure the approval of the US FDA to expand the late-stage clinical trial of their COVID-19 vaccine. Earlier, Pfizer has enrolled the 30,000 participants in the trial but now it is looking for the trial which will enroll 44,000 volunteers as the company is trying to add the young population in the late-stage study.

Previously, the US Government has revealed that it would pay $1.95 billion to companies for the supply of 100 million doses of vaccine if it received regulatory approval. CEO Pfizer also disclosed that the company has invested $1.5 billion for the development of a vaccine and if the trial is not successful it is painful for the company.

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

Tags: $PFECoronavirus VaccineFDANYSE: PFEPfizer IncPfizer Stock

Related Posts

Featured

Top Cyclical Stocks to Watch For in 2021

January 23, 2021
Top Performers Markets Awaits News from Congress and the Federal Reserve
Featured

GameStop (GME) Stock Continues to Spike Days after the Appointment of Ryan Cohen

January 22, 2021
Top 3 Reasons Why AzurRx Biopharma Inc [AZRX] is Gaining Bullish Momentum
Featured

Fluidigm (FLDM) Stock Gives Green Signal as it obtains CE-IVD ‎Mark for Its COVID-19 Test

January 22, 2021
Tesla Inc (NASDAQ:TSLA) Stock Is Soaring. Here’s Why.
Featured

Jaguar Health (JAGX) Closes its $6M Promissory Notes, What’s Next for JAGX Stock?

January 21, 2021
Top 3 Big Data Stocks for long-term Investment
Featured

Top 3 Big Data Stocks for long-term Investment

January 21, 2021
TG Therapeutics (NASDAQ: TGTX) Ublituximab Receives Fast Track Designation In US
Featured

Adamis Pharmaceuticals Corp (ADMP) shares slide 14% as traders take profits

January 21, 2021
Next Post
Stocks to Watch as Fears of a Renewed China/U.S Trade War Dampens Markets

Nvidia (NASDAQ: NVDA) Stock Keep Rising Amid ARM Deal

Looking for $1 Stock? BIOLASE (BIOL) is a Decent Bet

by Ali Hassan
January 21, 2021
0

The dental device firm is bullish and looks solid for long-term growth. The medical device firm, BIOLASE Inc. (BIOL) had...

Read more

Early Morning Vibes: The 4 Best Stocks To Buy Now

9 Trending Stocks in Travel Services Industry That Can Be A Good Bets
by Shan Zee
January 20, 2021
0

On January 19, American stock indexes finished trading in the green zone. The S&P 500 Index rose 0.81% to 3799...

Read more

Early Morning Vibes: Top 4 Stocks To Watch Right Now

Why Tesla Inc (NASDAQ: TSLA) Stock Might Be A Great Pick?
by Shan Zee
January 19, 2021
0

For Martin Luther King Day, the U.S. treasuries were closed yesterday. In the meantime, on Wednesday, the Americans are waiting...

Read more

Early Morning Vibes: 4 Stocks We Like for Thursday

Energy Focus (NASDAQ: EFOI) Introduces Portfolio Of Germicidal UV-C Disinfection Products
by Hasnain R
January 21, 2021
0

On January 20, American stock markets closed at new all-time highs. The S&P 500 index rose 1.39% to 3852 points,...

Read more

Early Morning Vibes: The 4 Best Stocks To Buy Now

Blonder Tongue Receives U.S. Patent Grant For DMM Series Of Products
by Shan Zee
January 14, 2021
0

American stock markets ended trading largely in the green zone on January 13. The S&P 500 index improved to 3810...

Read more
  • About
  • Meet The Team
  • Privacy Policy

© 2020 Stocks Telegraph - All Rights Reserved

No Result
View All Result
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers

© 2020 Stocks Telegraph - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.